Switch theme
Sign up to access all valuation multiples
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
2001
349
LTM Revenue $206M
LTM EBITDA $112M
$525M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GNI Group has a last 12-month revenue of $206M and a last 12-month EBITDA of $112M.
In the most recent fiscal year, GNI Group achieved revenue of $157M and an EBITDA of $20.6M.
GNI Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GNI Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $173M | $157M | XXX | XXX | XXX |
| Gross Profit | $98.0M | $149M | XXX | XXX | XXX |
| Gross Margin | 57% | 95% | XXX | XXX | XXX |
| EBITDA | $96.2M | $20.6M | XXX | XXX | XXX |
| EBITDA Margin | 56% | 13% | XXX | XXX | XXX |
| Net Profit | $2.6M | $53.8M | XXX | XXX | XXX |
| Net Margin | 1% | 34% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, GNI Group's stock price is JPY 1816 (or $12).
GNI Group has current market cap of JPY 91.2B (or $606M), and EV of JPY 79.0B (or $525M).
See GNI Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $525M | $606M | XXX | XXX | XXX | XXX | $0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, GNI Group has market cap of $606M and EV of $525M.
GNI Group's trades at 2.6x LTM EV/Revenue multiple, and 4.7x LTM EBITDA.
Analysts estimate GNI Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for GNI Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $525M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 25.5x | XXX | XXX | XXX |
| P/E | 83.0x | XXX | XXX | XXX |
| P/E/Growth | 0.4x | XXX | XXX | XXX |
| EV/FCF | -16.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGNI Group's NTM/LTM revenue growth is 61%
GNI Group's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, GNI Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate GNI Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for GNI Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -79% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 74% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 67% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 70% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GNI Group acquired XXX companies to date.
Last acquisition by GNI Group was XXXXXXXX, XXXXX XXXXX XXXXXX . GNI Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was GNI Group founded? | GNI Group was founded in 2001. |
| Where is GNI Group headquartered? | GNI Group is headquartered in Japan. |
| How many employees does GNI Group have? | As of today, GNI Group has 349 employees. |
| Who is the CEO of GNI Group? | GNI Group's CEO is Dr. Ying Luo, PhD. |
| Is GNI Group publicy listed? | Yes, GNI Group is a public company listed on TKS. |
| What is the stock symbol of GNI Group? | GNI Group trades under 2160 ticker. |
| When did GNI Group go public? | GNI Group went public in 2007. |
| Who are competitors of GNI Group? | Similar companies to GNI Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of GNI Group? | GNI Group's current market cap is $606M |
| What is the current revenue of GNI Group? | GNI Group's last 12-month revenue is $206M. |
| What is the current EBITDA of GNI Group? | GNI Group's last 12-month EBITDA is $112M. |
| What is the current EV/Revenue multiple of GNI Group? | Current revenue multiple of GNI Group is 2.6x. |
| What is the current EV/EBITDA multiple of GNI Group? | Current EBITDA multiple of GNI Group is 4.7x. |
| What is the current revenue growth of GNI Group? | GNI Group revenue growth between 2023 and 2024 was -9%. |
| Is GNI Group profitable? | Yes, GNI Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
